Uncategorized

MapLight dives despite positive data for schizophrenia drug

Published

1 week ago

on

July 27, 2026

By

Temp User

Shares fell more than 66% Monday morning, which analysts suspect is due to investors seeing the data as not competitive with Bristol Myers’ Cobenfy.

Related Topics:

Leave a Reply

Fierce Biotech4 months ago

Scientists turn pig semen extract into eye drops that kill cancer in mice
Uncategorized9 years ago

These ’90s fashion trends are making a comeback in 2017
Endpoints News5 months ago

Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Uncategorized4 months ago

Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Uncategorized9 years ago

According to Dior Couture, this taboo fashion accessory is back
Uncategorized9 years ago

Steph Curry finally got the contract he deserves from the Warriors

Exit mobile version